Nirsevimab is a long-acting monoclonal antibody that provides passive immunisation against RSV lower respiratory tract disease for at least 5 months after a single dose (usually enough for an entire RSV season). It is approved for newborns and infants (up to 24 months of age).
No takes yet. Share an insight, caveat, or question.
NULL AUTHOR_ID (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: